Serotonin dysregulation in adolescents with major depression

Hormone response to meta-chlorophenylpiperazine (mCPP) infusion

Neera Ghaziuddin, Cheryl A. King, Kathleen B. Welch, Joan Zaccagnini, E. Weidmer-Mikhail, Alan M. Mellow, Mohammad Ghaziuddin, John F. Greden

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

This study examined central serotonin disturbance, as reflected by neuroendocrine hormones, among adolescents with major depression. Prolactin, cortisol, and growth hormone were measured following the infusion of a serotonin agonist, meta-chlorophenylpiperazine (mCPP). Twelve (M = 6, F = 6) medication-free adolescents with major depression (MDD) were compared with 12 (M = 6, F = 6) matched normal control subjects, ranging in age from 13 to 17 years. Baseline evaluations and a battery of laboratory tests were completed. mCPP, 0.1 mg/kg i.v., was administered in a placebo-controlled design. Analyses of the neuroendocrine hormones revealed that the depressed group had a higher baseline prolactin level and an augmented prolactin response to mCPP challenge than did the control group. The depressed group experienced a sharper baseline-cortisol decline between 08.00 and 11.00 h, and compared to control subjects they displayed an augmented response to the challenge. The depressed group reported more side effects than the control group during saline infusion, but not during mCPP infusion. Findings suggest that depressed adolescents have an elevated baseline prolactin level, and also experience enhanced prolactin and cortisol responses to the serotonergic challenge. These preliminary findings will be confirmed during our ongoing study. (C) 2000 Elsevier Science Ireland Ltd.

Original languageEnglish (US)
Pages (from-to)183-194
Number of pages12
JournalPsychiatry Research
Volume95
Issue number3
DOIs
StatePublished - Jul 11 2000

Fingerprint

Prolactin
Serotonin
Hormones
Hydrocortisone
Serotonin Receptor Agonists
Control Groups
Growth Hormone
Placebos
1-(3-chlorophenyl)piperazine

Keywords

  • Adolescent depression
  • Meta- Chlorophenylpiperazine
  • Neuroendocrine
  • Serotonin

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Serotonin dysregulation in adolescents with major depression : Hormone response to meta-chlorophenylpiperazine (mCPP) infusion. / Ghaziuddin, Neera; King, Cheryl A.; Welch, Kathleen B.; Zaccagnini, Joan; Weidmer-Mikhail, E.; Mellow, Alan M.; Ghaziuddin, Mohammad; Greden, John F.

In: Psychiatry Research, Vol. 95, No. 3, 11.07.2000, p. 183-194.

Research output: Contribution to journalArticle

Ghaziuddin, Neera ; King, Cheryl A. ; Welch, Kathleen B. ; Zaccagnini, Joan ; Weidmer-Mikhail, E. ; Mellow, Alan M. ; Ghaziuddin, Mohammad ; Greden, John F. / Serotonin dysregulation in adolescents with major depression : Hormone response to meta-chlorophenylpiperazine (mCPP) infusion. In: Psychiatry Research. 2000 ; Vol. 95, No. 3. pp. 183-194.
@article{da35113e005d439c88a7cf4f28308da9,
title = "Serotonin dysregulation in adolescents with major depression: Hormone response to meta-chlorophenylpiperazine (mCPP) infusion",
abstract = "This study examined central serotonin disturbance, as reflected by neuroendocrine hormones, among adolescents with major depression. Prolactin, cortisol, and growth hormone were measured following the infusion of a serotonin agonist, meta-chlorophenylpiperazine (mCPP). Twelve (M = 6, F = 6) medication-free adolescents with major depression (MDD) were compared with 12 (M = 6, F = 6) matched normal control subjects, ranging in age from 13 to 17 years. Baseline evaluations and a battery of laboratory tests were completed. mCPP, 0.1 mg/kg i.v., was administered in a placebo-controlled design. Analyses of the neuroendocrine hormones revealed that the depressed group had a higher baseline prolactin level and an augmented prolactin response to mCPP challenge than did the control group. The depressed group experienced a sharper baseline-cortisol decline between 08.00 and 11.00 h, and compared to control subjects they displayed an augmented response to the challenge. The depressed group reported more side effects than the control group during saline infusion, but not during mCPP infusion. Findings suggest that depressed adolescents have an elevated baseline prolactin level, and also experience enhanced prolactin and cortisol responses to the serotonergic challenge. These preliminary findings will be confirmed during our ongoing study. (C) 2000 Elsevier Science Ireland Ltd.",
keywords = "Adolescent depression, Meta- Chlorophenylpiperazine, Neuroendocrine, Serotonin",
author = "Neera Ghaziuddin and King, {Cheryl A.} and Welch, {Kathleen B.} and Joan Zaccagnini and E. Weidmer-Mikhail and Mellow, {Alan M.} and Mohammad Ghaziuddin and Greden, {John F.}",
year = "2000",
month = "7",
day = "11",
doi = "10.1016/S0165-1781(00)00163-3",
language = "English (US)",
volume = "95",
pages = "183--194",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Serotonin dysregulation in adolescents with major depression

T2 - Hormone response to meta-chlorophenylpiperazine (mCPP) infusion

AU - Ghaziuddin, Neera

AU - King, Cheryl A.

AU - Welch, Kathleen B.

AU - Zaccagnini, Joan

AU - Weidmer-Mikhail, E.

AU - Mellow, Alan M.

AU - Ghaziuddin, Mohammad

AU - Greden, John F.

PY - 2000/7/11

Y1 - 2000/7/11

N2 - This study examined central serotonin disturbance, as reflected by neuroendocrine hormones, among adolescents with major depression. Prolactin, cortisol, and growth hormone were measured following the infusion of a serotonin agonist, meta-chlorophenylpiperazine (mCPP). Twelve (M = 6, F = 6) medication-free adolescents with major depression (MDD) were compared with 12 (M = 6, F = 6) matched normal control subjects, ranging in age from 13 to 17 years. Baseline evaluations and a battery of laboratory tests were completed. mCPP, 0.1 mg/kg i.v., was administered in a placebo-controlled design. Analyses of the neuroendocrine hormones revealed that the depressed group had a higher baseline prolactin level and an augmented prolactin response to mCPP challenge than did the control group. The depressed group experienced a sharper baseline-cortisol decline between 08.00 and 11.00 h, and compared to control subjects they displayed an augmented response to the challenge. The depressed group reported more side effects than the control group during saline infusion, but not during mCPP infusion. Findings suggest that depressed adolescents have an elevated baseline prolactin level, and also experience enhanced prolactin and cortisol responses to the serotonergic challenge. These preliminary findings will be confirmed during our ongoing study. (C) 2000 Elsevier Science Ireland Ltd.

AB - This study examined central serotonin disturbance, as reflected by neuroendocrine hormones, among adolescents with major depression. Prolactin, cortisol, and growth hormone were measured following the infusion of a serotonin agonist, meta-chlorophenylpiperazine (mCPP). Twelve (M = 6, F = 6) medication-free adolescents with major depression (MDD) were compared with 12 (M = 6, F = 6) matched normal control subjects, ranging in age from 13 to 17 years. Baseline evaluations and a battery of laboratory tests were completed. mCPP, 0.1 mg/kg i.v., was administered in a placebo-controlled design. Analyses of the neuroendocrine hormones revealed that the depressed group had a higher baseline prolactin level and an augmented prolactin response to mCPP challenge than did the control group. The depressed group experienced a sharper baseline-cortisol decline between 08.00 and 11.00 h, and compared to control subjects they displayed an augmented response to the challenge. The depressed group reported more side effects than the control group during saline infusion, but not during mCPP infusion. Findings suggest that depressed adolescents have an elevated baseline prolactin level, and also experience enhanced prolactin and cortisol responses to the serotonergic challenge. These preliminary findings will be confirmed during our ongoing study. (C) 2000 Elsevier Science Ireland Ltd.

KW - Adolescent depression

KW - Meta- Chlorophenylpiperazine

KW - Neuroendocrine

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=0034636690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034636690&partnerID=8YFLogxK

U2 - 10.1016/S0165-1781(00)00163-3

DO - 10.1016/S0165-1781(00)00163-3

M3 - Article

VL - 95

SP - 183

EP - 194

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 3

ER -